The FDA has officially ushered in a new era of drug discovery with the approval of Veppanu (vepdegestrant), the first-ever “PROTAC” to reach the market. Developed by Arvinas in partnership with Pfizer, this milestone marks a departure from traditional pharmacology, moving beyond merely blocking disease-causing proteins to completely eliminating them.
Harnessing the Cell’s Waste Disposal
Most conventional drugs act like a “plug,” binding to a protein to block its activity. Veppanu, a proteolysis-targeting chimera (PROTAC), operates with far more clinical aggression. It essentially “handcuffs” the unwanted estrogen receptors—the primary drivers of certain breast cancers—and drags them to the cell’s natural waste disposal system, known as the proteasome, where they are shredded and destroyed.
Targeting Treatment Resistance
Specifically, the FDA cleared Veppanu for adults with metastatic, estrogen receptor-positive, HER2-negative breast cancer who have progressed on prior endocrine therapy. Its most significant impact is reserved for patients with ESR1 mutations, a subset known for developing stubborn resistance to standard treatments. For these patients, Veppanu offers a vital second-line option when other therapies fail to move the needle.
An Uncertain Commercial Path
Despite the scientific triumph, Veppanu faces a complex landscape. Originally intended for a broader patient population, clinical data narrowed its primary benefit to the ESR1-mutant subgroup. This niche focus, combined with stiff competition from oral hormone-degraders by Eli Lilly and Menarini, has sparked investor skepticism regarding its commercial dominance.
Consequently, Arvinas and Pfizer are currently seeking a third-party partner to lead the drug’s commercialization. For Arvinas, however, the approval is a massive validation of their platform. With the “PROTAC” mechanism now proven, the company is pivotally shifting focus toward experimental treatments for Parkinson’s disease and other rare neuromuscular conditions, proving that in 2026, the best way to fight a disease might simply be to throw it away.
Read the full article: Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
Lambda Biologics’ Oncology Solutions: Patient-derived cancer organoid-based drug evaluation service
Gastric Cancer Organoid | Breast Cancer Organoid | Hepatocarcinoma Cancer Organoid | Pancreatic Cancer Organoid
